|
2025
|
Invention
|
Anti-steap1 antigen-binding protein.
The disclosure provides novel antigen-binding proteins that... |
|
2024
|
Invention
|
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof.
The present invention is direct... |
|
|
Invention
|
Anti-trop2 x anti-pdl1 x anti-cd28 antibodies. Provided herein are novel anti-TROP2 x anti-PDLl x... |
|
|
Invention
|
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibod... |
|
|
Invention
|
Bispecific antibodies that bind to nkp46 and mica/b. Provided herein are anti-NKp46 × anti-MICA/B... |
|
|
Invention
|
Pd-1 targeted il18-fc fusion proteins. Provided herein are PD-1 targeted IL18-Fc fusion proteins ... |
|
|
Invention
|
Methods and compositions for treating multiple sclerosis.
The present invention provides methods... |
|
|
Invention
|
Methods and compositions for treating multiple sclerosis. The present invention provides methods ... |
|
|
Invention
|
Optimized antibody variable regions.
The present invention is directed to optimized anti-CD3 var... |
|
|
Invention
|
Fc variants with altered binding to fcrn.
The present application relates to optimized IgG immun... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and cd38.
The present invention is directed to heterodime... |
|
|
Invention
|
Anti-cd20 x anti-cd28 combination therapies.
Provided herein are novel anti-CD20 x anti-CD28 ant... |
|
|
Invention
|
Anti-cd20 x anti-cd28 combination therapies. Provided herein are novel anti-CD20 x anti-CD28 anti... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and cldn6.
Provided herein are novel CLDN6 binding domain... |
|
|
Invention
|
Fc variants with altered binding to fcrn.
The present application relates to a variant Fc region... |
|
|
Invention
|
Dosing of a bispecific antibody that binds pd1 and ctla4.
The present invention is directed to m... |
|
|
Invention
|
Immunoprotection of therapeutic moieties using enhanced fc regions.
The present application rela... |
|
|
Invention
|
Heterodimeric antibodies that bind msln and cd3.
The present invention is directed to antibodies... |
|
|
Invention
|
Orthogonal multimeric proteins.
Provided herein are multimeric proteins that reduce the promiscu... |
|
|
Invention
|
Orthogonal multimeric proteins. Provided herein are multimeric proteins that reduce the promiscuo... |
|
|
Invention
|
Anti-cd28 x anti-enpp3 antibodies.
Provided herein are novel anti-CD28×anti-ENPP3 antibodies and... |
|
|
Invention
|
Anti-cd28 x anti-trop2 antibodies.
Provided herein are novel anti-CD28×anti-TROP2 antibodies and... |
|
|
Invention
|
Anti-cd28 x anti-trop2 antibodies. Provided herein are novel anti-CD28 x anti-TROP2 antibodies an... |
|
|
Invention
|
Anti-cd28 x anti-enpp3 antibodies. Provided herein are novel anti-CD28 x anti-ENPP3 antibodies an... |
|
|
Invention
|
Engineered il-2 fc fusion proteins.
The present invention provides IL-2-Fc fusion proteins compr... |
|
|
Invention
|
Anti-cd28 compositions.
Provided herein are novel anti-CD28 x anti-STEAP1 and anti-CD28 x anti-C... |
|
|
Invention
|
Anti-cd28 compositions. Provided herein are novel anti-CD28 x anti-STEAPl and anti-CD28 x anti-CE... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and tumor antigens.
The present invention is directed to ... |
|
|
Invention
|
Anti-cd28 x anti-psma antibodies.
Provided herein are novel anti-CD28 x anti-PSMA antibodies and... |
|
|
Invention
|
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment ... |
|
|
Invention
|
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers.
The presen... |
|
|
Invention
|
Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties.
The present inventi... |
|
|
Invention
|
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3.
Provided h... |
|
|
Invention
|
Complement component c5 antibodies.
The present disclosure relates to antibodies and polynucleot... |
|
2023
|
Invention
|
Il18-fc fusion proteins.
Provided herein are variant human IL18 proteins including proteins and ... |
|
|
Invention
|
Il-18-fc fusion proteins. Provided herein are variant human IL18 proteins including proteins and ... |
|
|
Invention
|
Bispecific antibodies that bind to b7h3 and mica/b. Provided herein are anti-MICA/B × anti-B7H3 a... |
|
|
Invention
|
Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer. Pr... |
|
|
Invention
|
Natural killer cell antibodies with increased adcc activity.
Described herein are antibodies, in... |
|
|
P/S
|
Biochemicals, namely, antibodies and fragments thereof for
research and development; biochemical... |
|
|
P/S
|
Biochemicals, namely, antibodies and fragments thereof for research and development; biochemicals... |
|
|
Invention
|
Heterodimeric proteins.
In one aspect, the present invention provides heterodimeric antibodies c... |
|
|
Invention
|
An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic der... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and gpc3.
Provided herein are novel GPC3 binding domains,... |
|
|
Invention
|
Anti-cd28 x anti-trop2 antibodies.
Provided herein are novel anti-CD28 x anti-TROP2 antibodies a... |
|
2022
|
Invention
|
B-cell maturation antigen (bcma) binding domain compositions.
Provided herein are novel BCMA bin... |
|
|
Invention
|
Anti-tslpr (crlf2) antibodies.
The present disclosure provides antibodies and antigen-binding do... |
|
|
Invention
|
Heterodimeric antibodies that bind claudin18.2 and cd3.
The present invention is directed to ant... |
|
2021
|
Invention
|
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus er... |
|
2018
|
P/S
|
pharmaceuticals, namely, antibodies and proteins for the treatment of oncological and autoimmune ... |
|
2004
|
P/S
|
Chemicals used in industry and science; enzymes and reagents for scientific, industrial, agricult... |
|
|
P/S
|
Pharmaceutical preparations for biological response modifier therapy, anti-cancer therapy, and ch... |
|
2003
|
P/S
|
Biochemicals, namely, monoclonal antibodies and fragments thereof for research and development, f... |
|
|
P/S
|
Pharmaceuticals, namely, monoclonal antibodies and fragments thereof for therapeutic use for the ... |
|
2002
|
P/S
|
Pharmaceutical preparations for hormone replacement therapies, cancer gene therapy, diabetes ther... |
|
|
P/S
|
Biotechnological products, being industrial enzymes and proteins, including pulp and paper proces... |
|
1998
|
P/S
|
PHARMACEUTICAL PREPARATIONS FOR [ HORMONE REPLACEMENT THERAPIES, CANCER GENE THERAPY, DIABETES TH... |
|
|
P/S
|
Biotechnological products for medical or veterinary purposes, being pulp and paper processing enz... |
|
|
P/S
|
computer programming services for automated molecular design and biotechnology and pharmaceutical... |
